EyePoint Pharmaceuticals granted stock options to new employees as inducement awards, totaling 31,000 shares at $11.58 each.
Quiver AI Summary
EyePoint Pharmaceuticals, Inc. announced the granting of non-statutory stock options to seven new employees as inducement awards outside of its 2023 Long-Term Incentive Plan, in compliance with NASDAQ Listing Rule 5635(c)(4). On November 14, 2025, the company allocated options to purchase a total of 31,000 shares at an exercise price of $11.58 per share, which reflects the closing price on that date. The options, which are designed to vest over four years, require the employees to remain with EyePoint throughout the vesting period. EyePoint, focused on developing innovative treatments for serious retinal diseases, is actively progressing its lead product candidate, DURAVYU™, through pivotal Phase 3 trials, with results expected in mid-2026.
Potential Positives
- The grant of 31,000 stock options to new employees indicates a strategic move to attract talent, which is vital for the company's growth and innovation in developing therapeutics.
- Approval by the Compensation Committee highlights the company's commitment to aligning employee incentives with long-term organizational goals, potentially leading to enhanced performance.
- The upcoming clinical trials for the lead product candidate, DURAVYU™, underline the company's active pipeline and ongoing commitment to addressing serious retinal diseases, providing potential for significant market impact.
- The conditional acceptance of DURAVYU™ by the FDA as the proprietary name signifies progress in the regulatory process, which can boost investor confidence and interest in the company.
Potential Negatives
- The granting of stock options to new employees outside of the 2023 Long-Term Incentive Plan may raise concerns about corporate governance and the company's approach to employee compensation.
- The uncertainty surrounding FDA approval for DURAVYU™ and the timelines for potential approval could negatively impact investor confidence and the company's stock performance.
- The company is still in the clinical trial phase for its lead product candidate, which indicates ongoing risks and challenges in bringing the product to market.
FAQ
What stock options did EyePoint Pharmaceuticals grant to new employees?
EyePoint Pharmaceuticals granted non-statutory stock options to purchase 31,000 shares of common stock to seven new employees.
What is the exercise price of the stock options?
The exercise price of the stock options is $11.58 per share, based on the closing price on November 14, 2025.
What are the vesting conditions for the stock options?
The options vest over four years, with 25% vesting on the first anniversary and the remainder monthly thereafter, subject to continued employment.
What is EyePoint's lead product candidate?
EyePoint's lead product candidate is DURAVYU™, a sustained delivery treatment for serious retinal diseases, currently in Phase 3 trials.
Where is EyePoint Pharmaceuticals headquartered?
EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility located in Northbridge, Massachusetts.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EYPT Insider Trading Activity
$EYPT insiders have traded $EYPT stock on the open market 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $EYPT stock by insiders over the last 6 months:
- RAMIRO RIBEIRO (Chief Medical Officer) sold 2,722 shares for an estimated $31,602
- KAREN L. ZADEREJ purchased 5,000 shares for an estimated $29,950
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$EYPT Hedge Fund Activity
We have seen 71 institutional investors add shares of $EYPT stock to their portfolio, and 87 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 3,181,818 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $29,940,907
- PARADIGM BIOCAPITAL ADVISORS LP added 2,005,365 shares (+inf%) to their portfolio in Q3 2025, for an estimated $28,556,397
- ORBIMED ADVISORS LLC added 1,796,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $25,575,040
- PERCEPTIVE ADVISORS LLC removed 1,537,274 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $14,465,748
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,240,218 shares (-18.2%) from their portfolio in Q3 2025, for an estimated $17,660,704
- FINEPOINT CAPITAL LP removed 1,081,954 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $10,181,187
- BALYASNY ASSET MANAGEMENT L.P. added 756,087 shares (+inf%) to their portfolio in Q3 2025, for an estimated $10,766,678
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$EYPT Analyst Ratings
Wall Street analysts have issued reports on $EYPT in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 08/07/2025
- RBC Capital issued a "Outperform" rating on 06/17/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/29/2025
To track analyst ratings and price targets for $EYPT, check out Quiver Quantitative's $EYPT forecast page.
$EYPT Price Targets
Multiple analysts have issued price targets for $EYPT recently. We have seen 3 analysts offer price targets for $EYPT in the last 6 months, with a median target of $27.0.
Here are some recent targets:
- Lisa Walter from RBC Capital set a target price of $39.0 on 11/06/2025
- Daniil Gataulin from Chardan Capital set a target price of $27.0 on 08/07/2025
- Yi Chen from HC Wainwright & Co. set a target price of $23.0 on 08/06/2025
Full Release
WATERTOWN, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The Company granted stock options to purchase up to an aggregate of 31,000 shares of EyePoint common stock to seven new employees. The stock options were granted on November 14, 2025. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $11.58 per share, the closing price of EyePoint’s common stock on November 14, 2025. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued service with EyePoint through the applicable vesting dates.
About EyePoint
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), in next-generation bioerodible Durasert E ™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) with topline data for the LUGANO trial anticipated in mid-2026 with LUCIA to closely follow. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema (DME) is expected in the first quarter of 2026.
The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.
EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU ™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901.
DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
For EyePoint:
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
[email protected]
/
[email protected]
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
[email protected]
